利用处方序列对称分析检测国家处方数据集中的药物安全信号
本研究探索处方序列对称分析(PSSA)能否增强澳大利亚治疗用品管理局(TGA)的药物安全信号检测,以心力衰竭(HF)为案例。对2012至2016年PBS所有单成分药物进行分析,以呋塞米启用作为新发HF的替代指标,在654种药物中检测到26个潜在HF信号,其中5个获得生物学合理性等额外支持。
要点
- PSSA可识别需进一步评估的潜在药物安全信号。
- 654种药物中检测到26个潜在HF信号,5个有额外支持。
- 调整后序列比95%CI下限>1定义为信号。
核心结论
- PSSA能够识别需要进一步评估的潜在信号。
研究设计与样本
- 应用PSSA方法分析2012至2016年PBS所有单成分药物,以呋塞米启用作为新发HF的替代指标。
主要发现
- 在654种测试药物中,PSSA检测到26个潜在新HF信号。
- 5个信号获得生物学合理性、一致性和向TGA及WHO的不比例报告以及临床影响的额外支持。
关键数值与推荐
- 若调整后序列比的95%置信区间下限>1,则认为存在信号。
- 排除已知引起HF、用于HF治疗或用于可能导致HF疾病的药物。
临床怎么用
- PSSA可作为药物警戒信号检测的补充工具,识别需进一步评估的潜在信号。
局限性
- 应评估用于监管药物警戒的行政健康数据分析方法的优势和弱点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Medicine safety signal detection methods employed by the medicine regulator in Australia (Therapeutic Goods Administration [TGA], Department of Health) rely predominantly on analysis of spontaneous adverse event (AE) reports, sponsor notifications or information shared by international agencies. The limitations of these methods and the availability of large administrative health data sets has given rise to greater interest in the use of administrative health data to support pharmacovigilance (PV). OBJECTIVE: We explored whether prescription sequence symmetry analysis (PSSA) of Pharmaceutical Benefits Scheme (PBS) data can enhance signal detection by the TGA, using the AE, heart failure (HF) as a case study. METHODS: We applied the PSSA method to all single-ingredient medicines dispensed under the PBS between 2012 and 2016, using furosemide initiation as a proxy for new-onset HF. A signal was considered present if the lower limit of the 95% confidence interval for the adjusted sequence ratio was > 1. We excluded medicines known to cause HF, indicated for HF treatment or indicated for diseases that may contribute to HF. RESULTS: Of the 654 tested medicines, 26 potential new HF signals were detected by PSSA. Five signals had additional support for the possible association provided by biological plausibility, consistency and disproportionate reporting of cases of HF to the TGA and the World Health Organization; and clinical impact. CONCLUSION: PSSA was able to identify potential signals for further evaluation. With the increasing availability of different administrative health data sources, the strengths and weaknesses of methods used to analyse these data for the purpose of regulatory PV should be evaluated.
引用
- King CE, Pratt NL, Craig N, et al. Detecting Medicine Safety Signals Using Prescription Sequence Symmetry Analysis of a National Prescribing Data Set. Drug Saf. 2020. PMID: 32578157. doi:10.1007/s40264-020-00940-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。